🧴image loading
(from DailyMed)

Nystatin and triamcinolone acetonide 100000 [USP'U]/g; 1 mg/g Cream

by Macleods Pharmaceuticals Limited · 1 TUBE in 1 CARTON (33342-482-30) / 30 g in 1 TUBE
NDC 33342-0482-30
🏷️ FDA NDC (as labeled) 33342-482-30 billing pads the product segment with a zero
This package
Contains30 g in 1 tube Cost per g$0.2233 NADAC Per package$6.70 / 30 g Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.5481/unit — full pricing hub ↓
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 33342-482-30
Product NDC 33342-482
11-digit billing NDC 33342048230
NCPDP billing unit GM — per gram (weight)
RxCUI 1053753
UNII BDF1O1C72E, F446C597KA
UPC 0333342482303, 0333342482150
Application # ANDA214181
SPL Set ID 57c4ebe8-7a8d-4fc0-b6cf-a276b68327fb
Established class (EPC) Polyene Antifungal; Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
Chemical class Polyenes
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2022-08-31
Route TOPICAL
Dosage form CREAM
Substance NYSTATIN; TRIAMCINOLONE ACETONIDE
GPI-14 90159902253700
GCN Seq No 048529
GCN 14007
HICL code 003161
Ingredient (HICL) Nystatin/Triamcinolone Acet
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 48:10.08.00
AHFS class Corticosteroids (Respiratory Tract)
FDB label name NYSTATIN-TRIAMCINOLONE CREAM
FDB brand name Nystatin-Triamcinolone
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AT · RLD · RS
Why two NDCs? The FDA registers this code as 33342-482-30 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 33342-0482-30. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids for local oral treatment, Corticosteroids, Corticosteroids, moderately potent (group II)
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerMacleods Pharmaceuticals Limited
Application holderMACLEODS PHARMACEUTICALS LTD
FDA applicationANDA214181 (ANDA)
Labeler code33342
First marketedAug 2022
Product typeHuman Prescription Drug
Portfolio381 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name NYSTATIN-TRIAMCINOLONE CREAM Ingredient Nystatin/Triamcinolone Acet
📖 What it is MedlinePlus · NLM

The combination of nystatin and triamcinolone is used to treat fungal skin infections. It relieves itching, inflammation, and pain. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • This combination cream or ointment treats cutaneous candidiasis — a fungal skin infection caused by Candida yeast. The nystatin kills the yeast, and the triamcinolone steroid helps...
  • What exactly is this medication treating?
  • Apply it to the affected area twice a day — once in the morning and once in the evening. For the cream, massage it gently and thoroughly into the skin. For the ointment, apply a th...
  • Most people tolerate this medication well. You might notice some mild burning, stinging, or dryness at the spot where you apply it. Less commonly, some people see acne-like bumps o...
📖 Read our full Nystatin and Triamcinolone guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 5QB0T2IUN0
    Aluminum hydroxide is a white powder mineral compound used as an antacid ingredient in some formulations. It works as a buffer and pH regulator to help neutralize stomach acid in the medicine.
  • UNII 867H4YOZ8Z
    A waxy compound made from plant or animal oils mixed with ethylene oxide. It helps oils and water blend together in creams and lotions, and makes the product easier to spread and absorb.
  • UNII 92RU3N3Y1O
    Dimethicone is a silicone-based oil that acts as an anti-foaming agent and lubricant in medicines. It reduces gas bubbles in liquid formulations and helps coat and protect the stomach lining when ingested.
  • UNII 230OU9XXE4
    A waxy substance made from glycerin and stearic acid that acts as an emulsifier to blend oily and watery ingredients together. It also helps thicken and stabilize the medicine's texture.
  • UNII A2I8C7HI9T
    Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
  • UNII 4T6H12BN9U
    Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.
  • UNII B697894SGQ
    Polyethylene glycol 400 is a clear, thick liquid made from petroleum-derived polymers. It acts as a solvent and humectant in medicines, helping dissolve active ingredients and retain moisture in the formulation.
  • UNII CAL22UVI4M
    A synthetic emulsifier derived from sorbitol and fatty acids. It helps mix oil and water-based ingredients together and improves the texture and stability of the medicine.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII Z8IX2SC1OH
    Propylparaben is a chemical preservative used to prevent bacterial and fungal growth in medicines and personal care products. It helps extend shelf life and maintain product safety during storage.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII X045WJ989B
    Sorbic acid is a preservative derived from berries that prevents mold, yeast, and bacterial growth in medicines. It keeps the product stable and safe during storage.
  • UNII 506T60A25R
    Sorbitol is a natural sugar alcohol derived from glucose. It serves as a sweetener, humectant, and bulking agent in medications to improve taste and help maintain moisture in the product.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

15 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.223 $6.70 / 30 g
Medicaid paysCMS SDUD · 12 mo $0.5481 $16.44 / 30 g
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per g) — tap or hover for the price & month
Dec 2025 Feb 2026 May 2026 Aug 2026 $0.235 $0.213
▼ Down 5% over the last 9 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Nystatin and triamcinolone acetonide 100000 [USP'U]/g; 1 mg/gthis 33342-0482-30 Macleods 1 tube $0.223 AT Availability likely
Nystatin And Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 45802-0880-14 Padagis 1 tube $0.280 AT Availability likely +25%
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 51672-1263-01 Sun 1 tube $0.280 AT Availability likely +25%
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 62332-0606-15 Alembic 1 tube $0.280 AT Availability likely +25%
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 68462-0799-17 Glenmark 1 tube $0.289 FDA listed +29%
Nystatin and triamcinolone acetonide 100000 [USP'U]/g; 1 mg/g 33342-0483-15 Macleods 1 tube $0.318 AT Availability likely +42%
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 72578-0088-01 Viona 1 tube $0.318 AT Availability likely +42%
nystatin and triamcinolone acetonide 100000 [USP'U]/g; 1 mg/g 45802-0244-14 Padagis 1 tube $0.318 AT Availability likely +42%
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 62332-0585-15 Alembic 1 tube $0.318 AT Availability likely +42%
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 21922-0031-04 Encube 1 tube $0.318 AT Availability likely +42%
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 51672-1272-01 Sun 1 tube $0.318 AT Availability likely +42%
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 68180-0545-01 Lupin 1 tube $0.467 AT Discontinued +109%
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 68462-0314-17 Glenmark 1 tube $0.490 FDA listed +119%
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 00316-0223-15 Crown 1 tube AT FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 13668-0610-01 Torrent 1 tube FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 46708-0606-15 Alembic 1 tube AT FDA listed
Nystatin And Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 63629-8688-01 Bryant 1 tube AT FDA listed
Nystatin And Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 63629-8689-01 Bryant 1 tube AT FDA listed
Nystatin And Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 63629-8690-01 Bryant 1 tube AT FDA listed
Nystatin And Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 68071-2491-03 NuCare 1 tube AT FDA listed
Nystatin and triamcinolone acetonide 100000 [USP'U]/g; 1 mg/g 68071-3972-03 NuCare 1 tube AT FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 68071-5037-03 NuCare 30 g AT FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 68788-8245-03 Preferred 1 tube FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 68788-8553-03 Preferred 1 tube AT Discontinued
Nystatin and triamcinolone acetonide 100000 [USP'U]/g; 1 mg/g 68788-8662-03 Preferred 1 tube AT FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 68788-8808-03 Preferred 1 tube AT FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 70518-1114-00 REMEDYREPACK 1 tube AT FDA listed
Nystatin And Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 71335-2894-01 Bryant 1 tube AT FDA listed
Nystatin And Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 72162-1433-02 Bryant 1 tube AT FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 63629-2497-01 Bryant 1 tube AT FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 71335-2857-01 Bryant 1 tube AT FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 63629-2495-01 Bryant 1 tube AT FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 71335-2847-01 Bryant 1 tube AT FDA listed
nystatin and triamcinolone acetonide 100000 [USP'U]/g; 1 mg/g 72162-1403-02 Bryant 1 tube AT FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 70771-1447-01 Zydus 1 tube AT FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 63629-2496-01 Bryant 1 tube AT FDA listed
Nystatin and Triamcinolone Acetonide 100000 [USP'U]/g; 1 mg/g 72162-1275-02 Bryant 1 tube AT FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2022
On the market since
Aug 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 33342-0482-30, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
3.9K
Units reimbursed last 4 qtrs
140.9K
Gross reimbursed last 4 qtrs
$77.2K
Avg / prescription
$19.62
Avg / unit
$0.5481
Latest quarter Q4 2025
1.2KRx
Medicaid pays / g
$0.5481
gross reimbursed
vs
NADAC / g
$0.2233
acquisition cost
=
Spread
+$0.3248
+145% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
40% FFS 60% MCO
Fee-for-service · 1,587 Rx Managed care · 2,349 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 2,520 units · 25.1 per 100k residents MI New York: 12,555 units · 64.2 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 7,890 units · 66.9 per 100k residents OH Pennsylvania: 6,450 units · 49.8 per 100k residents PA New Jersey: no data reported NJ Massachusetts: 14,355 units · 205 per 100k residents MA California: 9,211 units · 23.6 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 3,075 units · 67.9 per 100k residents KY West Virginia: no data reported WV Virginia: 10,545 units · 121 per 100k residents VA Maryland: 2,280 units · 36.9 per 100k residents MD Connecticut: 21,150 units · 585 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 4,590 units · 64.4 per 100k residents TN North Carolina: 3,270 units · 30.2 per 100k residents NC South Carolina: 12,105 units · 225 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: 7,770 units · 170 per 100k residents LA Mississippi: 4,005 units · 136 per 100k residents MS Alabama: 5,490 units · 107 per 100k residents AL Georgia: 5,310 units · 48.1 per 100k residents GA D.C.: 2,160 units · 318 per 100k residents DC Hawaii: no data reported HI Texas: 750 units · 2.5 per 100k residents TX Florida: 5,398 units · 23.9 per 100k residents FL
Units reimbursed · per 100k residents
2.5585
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Connecticut 585 /100k
2 D.C. 318 /100k
3 South Carolina 225 /100k
4 Massachusetts 205 /100k
5 Louisiana 170 /100k
6 Mississippi 136 /100k
7 Virginia 121 /100k
8 Alabama 107 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube this page33342-0482-30 3,936 Rx · $77,213
1 tube33342-0482-15 2,758 Rx · $43,677
1 tube33342-0482-60 1,226 Rx · $32,402
Drug total (last 4 qtrs): 7,920 Rx · 277,829 units · $153,292 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Nystatin and Triamcinolone Acetonide — the ingredient across all brands.

Top reported reactions

Application Site Pain8
Pruritus8
Drug Ineffective For Unapproved Indication6
Pain5
Rash5
Application Site Pruritus4
Burning Sensation4

Age at onset

Adult3
Elderly4

Reporter sex

104 reports

Serious outcomes

Hospitalization6
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 12 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
33342-0482-15 1 TUBE in 1 CARTON (33342-482-15) / 15 g in 1 TUBE $0.2801 / g $4.20 2022-08-31 Active
33342-0482-30 You're viewing this 1 TUBE in 1 CARTON (33342-482-30) / 30 g in 1 TUBE $0.2233 / g $6.70 2022-08-31 Active
33342-0482-60 1 TUBE in 1 CARTON (33342-482-60) / 60 g in 1 TUBE $0.1893 / g $11.36 2022-08-31 Active

Per g, this pack runs about 18% above the cheapest pack (NDC 33342-0482-60, $0.1893 vs $0.2233 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 50% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in NDC 33342-0482-30?
NDC 33342-0482-30 is listed by the FDA — 1 tube in 1 carton / 30 g in 1 tube.
What NDC number is used to bill for this package of Nystatin and triamcinolone acetonide 100000 [USP'U]/g; 1 mg/g Cream?
Bill NDC 33342-0482-30 — the 11-digit billing format is 33342048230. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 40 words

INDICATIONS AND USAGE Nystatin and triamcinolone acetonide cream, USP is indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.

⏱️ Dosage and Administration 62 words

DOSAGE AND ADMINISTRATION Nystatin and triamcinolone acetonide cream is usually applied to the affected areas twice daily in the morning and evening by gently and thoroughly massaging the preparation into the skin. The cream should be discontinued if symptoms persist after 25 days of therapy (see PRECAUTIONS, Laboratory Tests ). Nystatin and triamcinolone acetonide cream should not be used with occlusive dressings.

Contraindications 18 words

CONTRAINDICATIONS This preparations is contraindicated in those patients with a history of hypersensitivity to any of their components.

🤒 Adverse Reactions 95 words

ADVERSE REACTIONS A single case (approximately one percent of patients studied) of acneiform eruption occurred with use of combined nystatin and triamcinolone acetonide in clinical studies. Nystatin is virtually nontoxic and nonsensitizing and is well tolerated by all age groups, even during prolonged use. Rarely, irritation may occur.

The following local adverse reactions are reported infrequently with topical corticosteroids (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, perioral secondary infection, skin atrophy, striae and miliaria.

🤰 Pregnancy 86 words

Pregnancy: There are no teratogenic studies with combined nystatin and triamcinolone acetonide. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.

Therefore, any topical corticosteroid preparation should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Topical preparations containing corticosteroids should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

🧒 Pediatric Use 146 words

Pediatric Use In clinical studies of a limited number of pediatric patients ranging from two months through 12 years, nystatin and triamcinolone acetonide cream cleared or significantly ameliorated the disease state in most patients. Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids.

Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen.

Chronic corticosteroid therapy may interfere with the growth and development of children.

🆘 Overdosage 30 words

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS, General ); however, acute overdosage and serious adverse effects with dermatologic use are unlikely.

🧬 Clinical Pharmacology ~1 min read

CLINICAL PHARMACOLOGY Nystatin Nystatin exerts its antifungal activity against a variety of pathogenic and nonpathogenic yeasts and fungi by binding to sterols in the cell membrane. The binding process renders the cell membrane incapable of functioning as a selective barrier. Nystatin provides specific anticandidal activity to Candida (Monilia) albicans and other Candida species , but is not active against bacteria, protozoa, trichomonads, or viruses.

Nystatin is not absorbed from intact skin or mucous membranes. Triamcinolone Acetonide Triamcinolone acetonide is primarily effective because of its anti-inflammatory, antipruritic and vasoconstrictive actions, characteristic of the topical corticosteroid class of drugs. The pharmacologic effects of the topical corticosteroids are well known; however, the mechanisms of their dermatologic actions are unclear.

Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings (see DOSAGE AND ADMINISTRATION ).

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids (see DOSAGE AND ADMINISTRATION ).

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Some of the topical corticosteroids and their metabolites are also excreted into the bile. Nystatin and Triamcinolone Acetonide During clinical studies of mild to severe manifestations of cutaneous candidiasis, patients treated with nystatin and triamcinolone acetonide showed a faster and more pronounced clearing of erythema and pruritus than patients treated with nystatin or triamcinolone acetonide alone.

📦 How Supplied / Storage and Handling 93 words

HOW SUPPLIED Nystatin and triamcinolone acetonide cream USP supplied in 15 gram, 30 gram and 60 gram tubes. 15 gram Tube NDC 33342-482-15 (1 tube per carton) 30 gram Tube NDC 33342-482-30 (1 tube per carton) 60 gram Tube NDC 33342-482-60 (1 tube per carton) STORAGE Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Avoid freezing.

Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540 Manufacturer by: Macleods Pharmaceuticals Limited At Oxalis Labs Baddi, Himachal Pradesh, INDIA Rev. 09/2023

📋 Description 203 words

DESCRIPTION Nystatin and triamcinolone acetonide cream, USP for dermatologic use contain the antifungal agent nystatin and the synthetic corticosteroid triamcinolone acetonide. Nystatin, USP is a polyene antimycotic obtained from Streptomyces noursei. It is a yellow to light tan powder, Freely soluble in dimethylformamide and in dimethyl sulfoxide; very slightly soluble in methanol; practically insoluble or insoluble in water, in alcohol, in n-propyl alcohol, in n-butyl alcohol, in chloroform and in ether.

Structural formula: C 47 H 75 NO 17 MW= 926.13 Triamcinolone acetonide, USP is designated chemically as 9-fluoro-11β, 16α, 17, 21- tetrahydroxypregna-1, 4-diene-3, 20-dione cyclic 16, 17-acetal with acetone. The white to cream crystalline powder has a slight odor, Sparingly soluble in dehydrated alcohol, in chloroform and in methanol, Practically insoluble in water. Structural formula: C 24 H 31 FO 6 MW= 434.50 Nystatin and triamcinolone acetonide cream, USP is a soft, smooth, light yellow to buff colored cream.

Each gram provides 100,000 USP Nystatin units and 1 mg Triamcinolone Acetonide USP in a cream base with aluminium hydroxide, ceteareth 15, glyceryl monostearate, methyl paraben, non-crystallizing sorbitol solution, polysorbate 60, polyethylene glycol 400 monostearate, propylene glycol, propyl paraben, simethicone emulsion, sorbic acid, titanium dioxide white petrolatum, purified water. nystatin structure triam structure

💬 Information for Patients 158 words

Information for the Patient Patients using this medication should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for dermatological use only.

Avoid contact with the eyes. 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.

3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occluded (see DOSAGE AND ADMINISTRATION ). 4.

Patients should report any signs of local adverse reactions. 5. When using this medication in the inguinal area, patients should be advised to apply the cream sparingly and to wear loosely fitting clothing.

6. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings. 7.

Patients should be advised on preventive measures to avoid reinfection.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.